Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis

Background and aimsThe effects of Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) on lipid profiles have been observed in chronic hepatitis B (CHB) treatment. However, the metabolic features and their impact on cardiovascular risk remain unclear. We conducted a systematic review a...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yuan-Hai Zhou, Nan Cai, Yu-Xin Chen, Yong-Lu Su, Peng Hu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-06-01
Schriftenreihe:	Frontiers in Pharmacology
Schlagworte:	dyslipidemia metabolic profile cardiovascular risk tenofovir drug safety chronic hepatitis B
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1604972/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!